Polaryx Therapeutics, Inc. (PLYX)
2.09
-0.05
(-2.34%)
USD |
NASDAQ |
Sep 25, 16:00
Polaryx Therapeutics Enterprise Value : 92.64M for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 92.64M |
| September 24, 2026 | 95.13M |
| September 23, 2026 | 95.13M |
| September 22, 2026 | 95.63M |
| September 21, 2026 | 95.13M |
| September 18, 2026 | 90.14M |
| September 17, 2026 | 95.13M |
| September 16, 2026 | 89.65M |
| September 15, 2026 | 90.39M |
| September 14, 2026 | 89.15M |
| September 11, 2026 | 88.65M |
| September 10, 2026 | 87.65M |
| September 09, 2026 | 92.14M |
| September 08, 2026 | 89.15M |
| September 04, 2026 | 88.15M |
| September 03, 2026 | 87.65M |
| September 02, 2026 | 90.14M |
| September 01, 2026 | 87.15M |
| August 31, 2026 | 88.65M |
| August 28, 2026 | 91.14M |
| August 27, 2026 | 93.63M |
| August 26, 2026 | 92.64M |
| August 25, 2026 | 87.65M |
| August 24, 2026 | 81.67M |
| August 21, 2026 | 91.64M |
| Date | Value |
|---|---|
| August 20, 2026 | 95.13M |
| August 19, 2026 | 96.13M |
| August 18, 2026 | 92.64M |
| August 17, 2026 | 93.13M |
| August 14, 2026 | 118.06M |
| August 13, 2026 | 113.07M |
| August 12, 2026 | 99.61M |
| August 11, 2026 | 98.12M |
| August 10, 2026 | 94.13M |
| August 07, 2026 | 101.11M |
| August 06, 2026 | 99.12M |
| August 05, 2026 | 100.11M |
| August 04, 2026 | 99.61M |
| August 03, 2026 | 97.62M |
| July 31, 2026 | 103.60M |
| July 30, 2026 | 95.63M |
| July 29, 2026 | 87.65M |
| July 28, 2026 | 87.65M |
| July 27, 2026 | 86.16M |
| July 24, 2026 | 90.64M |
| July 23, 2026 | 93.63M |
| July 22, 2026 | 100.11M |
| July 21, 2026 | 104.10M |
| July 20, 2026 | 101.11M |
| July 17, 2026 | 102.11M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 15.23M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -64.07M |
| Fulcrum Therapeutics, Inc. | -28.26M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.38M |
| Total Expenses (Quarterly) | 1.38M |
| EPS Diluted (Quarterly) | -0.0286 |
| Earnings Yield | -6.90% |
| Normalized Earnings Yield | -5.751 |